l Introduction
The diagnosis of neonatal septicaemia must be considered in almost every sick newborn infant [4] , but definitive aetiological diagnosis and management, particularly treatment with antibao terial antibiotics, poses problems. While the combination of penicillin and an aminoglycoside should meet most bacterial eventualities [2] , the presumptive diagnosis of septicaemia or other serious microbial disease is unconfinned in most of the babies to whom the drugs have been given, and there is no doubt that a safe, effective alternative to the aminoglycosides is required. Because of the emergence of lesistance in microbes previously deemed sensitive, ampicfllin is no longer so useful äs it once was. It is important that the first choice antibiotics should not be toxic, and that aminoglycosides be reserved for life threatenmg situations and for cases in which there is a high probabäity of infection with organisms resistant to other antimicrobial agents. The amidinopenicillin, mecillinam (Selexidin, LEO LAiBORATORjEs), first described by LUND and TYBRING [7] , has an aatibacterial spectrum confined to the enterte Gram-negative aerobic rods [12] apd is bactericidal to a high percentage of ampicilito resistnit strains of Escherichia coli {9]. Its toxicity is no greater than that of the penicülins and it does not ex^rt teratogenic . effects 13] . Synergy betwe.en mesiüifiam and otherlactam drugs has been denjcmstrated in vitro « [6, 10, 13] In this preliminary study, we evaluate aspects of the pharmacokinetics of mecillinam, used in combination with penicülin, in the treatment of seventy neonates in a Special Gare Baby Uni t. Particular regard has been paid to the safety of the agent
Subjects
Thirty-four male and Üiirty-six female babies, with a inean gestational age of 34.5 ± 4.9 weeks and mean birthweight of 2.2 ± 0.9 kg were treated by intramuseular injection of mecillinam and peniciilin. The mode pf delivery included spontaneous vertex vaginal delivery, 24, breech delivery, 6, forceps deUvery, 15, elective lower segment caesarean section, 15, and emergency lower sßg-ment caesarean section, 6; the mode of delivery was not recorded in four babies transferred from other units. Fifty-four babies were preterm; thirteen of them being less than thirty weeks gestation and forty-five had a birthweight of less than 2.5 kg. In all cases birth and early neonatal life were accompanied by complications, often multiple, known to predispose to potentially lethal infections, or to presage them [4] . They included prolonged rupture of membranes, 26, birth asphyxia, 12, matemal pyrexia, 9, neonatal pyrexia, 4, meconium aspiration, 10, respiratory distress or hyaline membrane disease, 18, pneumothorax, 5, or fetal tachycardia, 4. Previous to this study, all the babies would have received either ampicillin and flucloxacillin or a penicillin and gentamicin, depending on the gravity of the clinical state.
Treatment regimen
The dosage regimen was mecillinam* (40 mg/kg/ day) and penicillin (60000 units/kg/day) separately administered in divided doses by intramuscular injection at six hourly intervals for five days. In eleven patients treatment was not completed and for two patients further courses were prescribed.
Laboratory investigations
The incidence of mecillinam resistant organisms isolated from patients within the Special Gare Baby Unit was determined before the introduction of mecillinam and during the first six months of use. Surface swabs and blood cultures were collected prior to treatment. Capillary samples of blood were collected for estimation of serum urea, total protein, albumin and alanine aminotransferase (ALAT) before mecillinam therapy was begun, during the third or fourth day of treatment and two days after the course of treatment had been completed. The results of other biochemical, haematological and microbiological investigations requested by paediatricians on the patients were also analysed.
Mecillinam assay
One hundred and twenty f -one samples of blood from 59 babies were collected for assay of mecillinam at timed intervals by heel prick or via an arterial line. The assay was performed by a plate diffusion technique using Enterobacter species (LEO LABORATORIES HC12) äs test organism and an assay medium consisting of 0.5% yeast extract (Difco) in 1% agar. The indicator organism was sensitive to mecillinam (MIC 0.5 mg/1), resistant to penicillin and did not exhibit synergy. Assays were set up within two hours of collection using horse serum Standards prepared while the clinical samples were being cöllected.
Sensitivity testing
Sensitivity of Gram-negative rods to mecillinam was determined on Diagnostic Sensitivity Test (DST) medium (Oxoid) using a 10 mcg disc. Initl· ally E. coli (NCTC 10418) was used äs a control. Later results were read from a regression line available from Leo Laboratories. The minimal inhibitory concentration of mecillinam was determined by the method of NEU [10] for all organisms appearing less sensitive than the control.
Results
Bacteriological investigations were undertaken in sixty-six babies, before treatment with mecillinam 2 (1981) was commenced. Two hundred and ninety-eight specimens were examined. Pathogens or potential pathogens were cultured from nineteen babies (29%) in thirty-seven instances (Tab. I), and details of the bacteria isolated are shown in Tab. II.
More than one pathogen was cultured from six babies. Gram-negative rods sensitive to mecillinam were isolated from seven babies in fifteen instances. None of the babies had meningitis but blood culture was positive in nine babies (14%) (Tab. III). Details of those in whom infection was confirmed, or who were deemed at high risk of serious infection supervening because pathogenic bacteria had been isolated from parental tubes, infected cord site or from multiple superficial sites are given in Tab. III.
The sensitivity of appropriate microbes to mecillinam was established over a period of four months before the introduction of mecillinam, and du ring and after the trial, over an eight month period. Approximately three hundred isolates of enteric, aerobic Gram-negative rods were tested, and there was no rise in the numbers of mecillinam resistant organisms isolated. The sensitivity of microbes t o the drug did not alter during treatment. Fifty-nine babies received the füll five day course of mecillinam with penicillin; in two of them, it was prolonged to ten and nineteen days respectively. Eleven other babies received less than the five day course: In six, with either proven systemic infection, 3, or deteriorating clinical state, 3, two of whom died subsequently, mecillinam was replaced by gentamicin for ethical reasons; in two, it See Table 2 See Table 2 (2) Coagulase negative staphylococci (2)* Proteus species (1) Neisseria gonorrhoeae was discontinued on discharge or on transfer for surgery; two died of non-bacterial disease (hyaline membrane disease; disseminated herpes) during treatment, and all treatment was withheld from a baby with DOWN'S syndrome. The overall mortality in the fully and partially treated babies was 11.4 per cent (8/70). Four deaths occurred in the 59 babies in whom therapy with mecillinam was completed: One baby died of bronchopulmonaiy dysplasia, one died following surgery and two died 4 months after being discharged from hospital. One of these was ad-mitted to another hospital and died of septicaemia. This baby had been treated successfully with mecillinam for Escherichia coli septicaemia, and succumbed, four months later, to an umelated fiirther episode of septicaemia, diagnosed at post mortem examination äs probably meningococcal in origin. Four of the eleven in whom mecillinam was discontinued also died, of disseminatedherpes, of hyaline membrane disease, of massive pulmonary haemorrhage and of intraventricular haemorrhage, the latter following hyaline membrane disease and bronchopulmonary dysplasia, respectively. Thus only one of the eight deaths was associated with infection. Biochernical tests were performed on sixty-six babies (Tab. IV). Summating the öbservations in the three groups tested, ihe majority of results feil within the normal ränge for ALAT (93%) total protein (79%) and albumin (92%); 3% had ALAT levels above the normal ränge and 8% had abnormally low albumin levels. In 15% of .specimens tested, total protein concentration was afaove the normal ränge and in 6% it was below this. natal age when treatment commenced. These cumulative results suggested that infants above the lOth centile bom at less than 31 weeks gestation had a lower peak serum level and longer half life than those of more than 34 weeks gestation (p for the slope <OX)5). This difference was not associated with birthweight. Infants below tiie lOth centile for birthweight, head circumference or length had lower serum levels if treatment was started after the fourth neonatal day than similar infants treated before this time (p < 0.002) or infants above the lOth centile irrespective of neonatal age. The trough levels of mecillinam were the same for each of these groups, The cumulative half life for the 59 neonates studied was between 3 and 4 hours. Among infants born at less than 31 weeks gestation the half life was slightly longer. The reported half life in aduits is 0.8 hr. [8] .
Discussion
PRYSE-AVIES and HURLEY [11] showed thatinfection was a primary cause of death in the perinatal period in 3.4 per cent of autopsies and a contributoiy cause in up to 20 per cent. Predominant amongst the microbes isolated was E. coli, often resistant to ampicillin, and further analysis of their data shows that its incidence, relative to that of other microbes 5 increased over the ten year period of their study. There is, therefore, a good a priori case for inclusion in the therapeutic armamentarium of antibiotics active against E. coli and other Gram-negative rods encountered in neonatal practice. It is important that such agents should be entirely safe, for treatment of the newborn is often based on presumptive diagnosis [4] and, no doubt, many are treated unnecessarily (2J. We regafd mecillinam äs a usefül alternative to the less safe gentamicin in cases where the latter drug is not definitely indicated.
Summary
In an attempt to find a safe alternative to gentamicin äs first line therapy the amidinopenicillin, mecillinam (Selexidin -LEO LABORATORIES) was used to treat 70 neonates with suspected or proven infection. These patients had a mean gestational age of 34.5 ± 4.9 weeks and a mean birthweight of less than 2.5 kg. All the babies studied had complications of birth or early neonatal life which are known to predispose to potentially lethal infection. The treatment regimen consisted of intramuscular mecillinam (40 mg/Kg/day) and penicillin (60 000 unit/ Kg/day) divided into six hourly doses and administered separately for five days. Prior to the study these neonates would have received gentamicin and penicillin or ampicillin and cloxacillin. Pathogenic or potentially pathogenic bacteria were isolated from 19 (29%) infants (Tab. I). Prior to starting treatment 74% of isolates were sensitive to mecillinam or penicillin. The majority of resistant organisms were staphylococci (Tab. II). None of the babies had meningitis but blood cultures from 9 were positive. Eight of the 70 neonates died; but only one of the deaths was associated with infection and this occurred 4 months after discharge from hospitaJ. No alteration in the sensitivity of appropriate bacteria to mecillinam was noted during the course of the study nor did the incidence of resistant bacteria in the unit change after the introductionof mecillinam. Estimations of serum alanine aminotransferase, total protein, albumin and urea were performed on 66 babies before, during and after mecillinam therapy. No agnificant differences were observed (Tab. IV). Mecillinam therapy did not affect the haemoglobin concentration, total or differential white cell count or serum sodium or potassium levels. No adverse clinical side effects were observed. One hundred and twenty-one samples of serum from 59 neonates were assayed for mecillinam at varying times after injection and the results analysed. There was wide Variation in peak serum level (mean 17 mg/1) and persistence of the drug. Peak seium levels occurred approximately 15 minutes aftesr intramuscular injection and six hours after injection the mean serum level was 4-8 mg/L The serum half life was between 3 and 4 hours depending on gestational age. Multiple regression analysis of the assay results suggested that in infants of <31 weeks gestation the peak serum levels were lower and the half lifes longer than in those born at more than 34 weeks gestation (P for the slope < 0.05). This difference was not associated with birthweight. The serum levei was lower in infants below the lOth centile for birthweight, head circumference or length if treatment was started after the fourth neonatal day compared with similar babies treated before this time (P < 0.002) or neonates above the lOth centile. Evaluation of mecillinam in the treatment of suspected or proven infections in neonates has shown that it is a safe drug which is well tolerated and rapidly absorbed following intramuscular injection. Following the study the combination of mecillinam and penicülin has been used routinely äs antibiotic treatment of first choice in our neonatal special care unit for fourteen months. We regard it äs a useful alternative to gentamicin in cases were the use of an aminoglycoside is not definitively indicated.
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